Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
SNY
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Last trade$47.67
Day change-$0.725 (-1.50%)
Day range$47.37 – $48.49
Volume1,236,900
Market cap$116.19B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for SNY.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for SNY.
Recent news
Company coverage with links to the original publishers.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
Regeneron Pharmaceuticals is highlighted as potentially the cheapest major biotech company, trading at approximately 21x trailing earnings with $16 billion in net cash. The company's stock has climbed over 40% in the past year, driven by strong performance from key products like Libtayo and Eylea HD, which posted record sales. With a robust pipeline of 50 candidates and a $1 billion upfront payment from an expanded Sanofi partnership, Regeneron appears well-positioned for future growth.
Moderna outlined its growth strategy at its 2026 Analyst Day, highlighting oncology as a key long-term opportunity with intismeran autogene for melanoma treatment. However, shares fell 7% as the company projected $4 billion in 2027 cash costs and $4-$4.5 billion annually through 2030, while providing limited visibility into 2027 and longer-term revenue growth.
Windward Bio Group AG, a clinical-stage biotechnology company developing ultra-long-acting antibody medicines, priced its IPO at $17.00 per share for 10.3 million shares, raising $225 million in gross proceeds. The company also completed a concurrent private placement with Sanofi for $50 million. Trading on Nasdaq under ticker WWB is expected to begin November 13, 2026, with offering closure on November 16, 2026.
Regeneron Pharmaceuticals (REGN) shares surged 27.4% over the past month, driven by strong third-quarter results. Eylea HD sales jumped 62% to $699 million, offsetting declining Eylea sales amid competition from Roche's Vabysmo. Strong Dupixent profits, oncology portfolio expansion, and a promising pipeline including cemdisiran for myasthenia gravis support long-term growth. The stock trades at an attractive valuation of 13.29X forward earnings, below historical and industry averages, earning a Zacks Rank #2 (Buy) rating.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
May 4, 2026
$2.419
Jun 3, 2026
recurring
May 9, 2025
$2.1953
Jun 12, 2025
recurring
May 9, 2024
$2.0369
Jun 6, 2024
recurring
May 30, 2023
$1.9001
Jun 23, 2023
recurring
May 4, 2022
$1.7468
May 31, 2022
recurring
Stock splits
Historical share-structure events and their execution dates.